CNBC May 31, 2024
Key Points
– The Food and Drug Administration approved Moderna’s vaccine for respiratory syncytial virus.
– The decision is a win for Moderna, which desperately needs another revenue source amid plunging demand for its Covid jab, its only commercially available product.
– An advisory panel to the Centers for Disease Control and Prevention will vote in June on recommendations for the use and intended population of Moderna’s shot, which follows similar jabs by Pfizer and GSK.
The Food and Drug Administration on Friday approved Moderna’s vaccine for respiratory syncytial virus for adults ages 60 and above, the company’s second-ever product to enter the U.S. market.
The decision is a win for Moderna, which desperately needs another revenue source...
Today's Sponsors
Today's Sponsor